A Phase II Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects With Age-Related Macular Degeneration

Principal Investigator: Richard Rosen, MD

Enrollment Status: Completed

Objective:  This is a Phase II multicenter, randomized, double-masked, placebo-controlled, dose-comparison study of the safety and efficacy of fenretinide in the treatment of Geographic Atrophy in subjects with AMD. Subjects will be given PreserVision® Lutein Soft Gels Eye Vitamins, without beta-carotene, to take throughout the study.

Study results are currently being analyzed. Please visit this webpage next month for the study update.

For more information: ClinicalTrials.gov